Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 64
- Slightly Positive
- ConsistencyScore™
- 57
- generally_consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide is safe for dialysis patients with type 2 diabetes
Last updated August 29, 2026
Key finding
SAEs were reported in 32 of 71 (45%) participants in the semaglutide group.
This study evaluated the safety of semaglutide in patients with type 2 diabetes who were initiating dialysis, revealing notable safety concerns.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the safety of semaglutide in patients with type 2 diabetes who were initiating dialysis, revealing notable safety concerns.
Clinical relevance
Understanding the safety of medications like semaglutide in vulnerable populations, such as those initiating dialysis, is crucial for clinicians. High rates of serious adverse events and mortality highlight the need for careful monitoring and consideration of treatment options in this patient group.
Keep in mind
Limited sample size of 71 participants may affect generalizability. The study did not assess long-term effects beyond the initial analysis. Data on potential confounding factors were not fully explored.
Published in
Journal Reference
Publication details and source links for this paper.
Klara RK, Anna M, John BB, et al. Safety of Semaglutide in Patients with Type 2 Diabetes Initiating Dialysis: A Post Hoc Analysis. Diabetes Care. 2026;49(6):999-1005. doi:10.2337/dc26-0112
Main Effects
Serious adverse events occurred in 32 of 71 participants (45%) in the semaglutide group.
MACE event rates were recorded at 9.7 events per 100 person-years in the semaglutide group.
All-cause mortality event rates were 13.8 events per 100 person-years in the semaglutide group.
8.5% of participants permanently discontinued semaglutide treatment.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and All-cause mortality, Cardiovascular events, Proportion of participants reaching treatment goals, and 1 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- All-cause mortality
- Cardiovascular events
- Proportion of participants reaching treatment goals
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
4
Evidence pairs
156
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Related evidence
Evidence topic
Cardiovascular Risk
Save evidence
Evidence topic
GLP-1 Receptor Agonists
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerProportion of participants reaching treatment goals
Semaglutide → Proportion of participants reaching treatment goals
Semaglutide → Proportion of participants reaching treatment goals
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- 45% of participants experienced serious adverse events while on semaglutide.
- All-cause mortality rate was 13.8 events per 100 person-years.
- 8.5% of participants discontinued semaglutide treatment permanently.
Who this applies to
- Adults with type 2 diabetes initiating dialysis.
- Patients who may require medication for diabetes management during dialysis.
Keep in Mind
- Results may not be applicable to patients not starting dialysis.
- The findings are based on a post hoc analysis, which may limit conclusions.
- Further studies are needed to confirm these safety outcomes in larger populations.
Between the Lines
- Limited sample size of 71 participants may affect generalizability.
- The study did not assess long-term effects beyond the initial analysis.
- Data on potential confounding factors were not fully explored.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 64
- Slightly Positive
- ConsistencyScore™
- 57
- generally_consistent
Supporting studies: Based on 7 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
7 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and All-cause mortality
Intervention: SemaglutideOutcome: All-cause mortality
7 results
All studies on Semaglutide and Cardiovascular events
Intervention: SemaglutideOutcome: Cardiovascular events
4 results
All studies on Semaglutide
Intervention: Semaglutide
7 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
7 results
All studies measuring Cardiovascular events
Outcome: Cardiovascular events
4 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve cardiovascular outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.3 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
- 2
Cardiovascular events
EvidenceScore™ Strong | EvidenceScore™ 78.7 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Does Semaglutide improve serious saes?
Moderate Evidence
Current evidence does not show a clear benefit of Semaglutide for serious saes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Serious SAEs
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Semaglutide improve proportion of participants reaching treatment goals?
Emerging Evidence
Current evidence does not show a clear benefit of Semaglutide for proportion of participants reaching treatment goals.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Proportion of participants reaching treatment goals
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.